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ABSTRACT  
We examined roles of calcitonin family peptides in the initial stages of dendrite 
formation and the maturation of dendritic spines in the rat cerebral cortex in vitro. 
Embryonic day 18 cortical neurons were dissociated and cultured for 2-3 days in the 
presence of calcitonin gene-related peptide (CGRP), calcitonin, amylin or 
adrenomedullin. The treatment of cortical neurons with CGRP promoted the formation 
of primary dendrites of non-GABAergic neurons. In contrast, the treatment with amylin 
and adrenomedullin for 3 days inhibited the dendritic elongation of non-GABAergic 
neurons. Calcitonin had no effect on the initial dendrite formation. Next, we examined 
roles of the peptides in the spine formation. Embryonic day 16 cortical neurons were 
cultured for 14 days and then treated acutely with CGRP, amylin or adrenomedullin for 
24 hours. The density of filopodia, puncta /stubby spines and spines were increased by 
the CGRP treatment, whereas decreased by amylin. Therefore, CGRP and amylin 
showed opposite effects on the formation of dendritic filopodia, puncta and spines. 
Adrenomedullin had no effects on the spine formation. In conclusion, the present study 
showed that calcitonin family peptides have differential effects both in the dendrite 
formation during the initial stages and the spine formation of cortical neurons in vitro.  
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1. Introduction 
  It has been shown that some neurotransmitters have neurotrophic activities during the 
brain development. Although the roles of classical neurotransmitters such as 
monoamines, glutamate and GABA have been extensively studied including the 
receptors mediating the neurotrophic activities (Lipton and Kater, 1989; Lujan et al., 
2005; Represa and Ben-Ari, 2005), little is known about the neuropeptides. We have 
recently shown that neurotensin promotes the dendrite elongation and the maturation of 
dendritic spines of cultured cerebral cortical neurons (Gandou et al., 2010). It is possible 
that there are other neuropeptides that regulate the formation of dendrites and dendritic 
spines. In the present study, we examined the roles of calcitonin gene-related peptide 
(CGRP) and other calcitonin (CT) family peptides in the formation of dendrites and 
dendritic spines of cortical neurons in vitro.    
  CGRP is a 37-amino acid peptide that was originally identified as an alternate 
splicing product of CT gene (Amara et al., 1982; Rosenfeld et al., 1983). It is a member 
of the structurally conserved CT family peptides that include adrenomedullin (AM), 
amylin (AMY) and CT (Wimalawansa, 1996; van Rossum et al., 1997). CGRP is widely 
distributed in the brain and the spinal cord as well as various peripheral tissues (Amara 
et al., 1985; Kawai et al., 1985; Skofitsch and Jacobowitz, 1985; Ma et al., 2003), and it 
has been shown that CGRP has diverse biological actions including the vasodilatation 
and nociception (van Rossum et al., 1997; Ma, 2004). The mRNA and protein of CGRP 
appear early in the brain during the development (Terrado et al., 1997; 1999). 
Subsequently the expression level increases transiently during the postnatal days, 
followed by the decrease in the adult brain. These expression patterns suggest roles of 
CGRP in the brain development, but there are a few studies which examined the CGRP 
actions in the neural development. It has been shown that CGRP promotes 
differentiation of dopaminergic neurons in the olfactory bulb and midbrain 
(Denis-Donini, 1989; Bürvenich et al., 1998). A recent study reported that CGRP 
promotes the dendrite formation of cerebellar Purkinje cells (D’Antoni et al., 2010). 
  The receptors of CGRP, AM, AMY and CT are closely related (Poyner et al., 2002; 
Parameswaran & Spielman, 2006). The CGRP receptor is a heterodimer composed of 
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the calcitonin-like receptor (CLR) and the receptor activity modifying protein 1 
(RAMP1) (McLatchie et al., 1998; Juaneda et al., 2000; Kuwasako et al., 2004). CLR is 
a seven trans-membrane G protein coupled receptor and RAMP1 is a chaperone/ligand 
specificity protein. The AM receptors are also heterodimers composed of CLR in 
combination with RAMP2 or RAMP3, while the AMY receptors are composed of the 
calcitonin receptor (CTR) and each of RAMP1-3. In contrast, the receptor of CT is a 
CTR monomer. These receptors are coupled with Gs and regulate the intracellular 
cAMP concentration, but mediate diverse physiological responses.  
  In the present study, we examined the actions of CGRP in the initial stages of 
dendrite formation and the maturation of dendritic spines by dissociation culture of 
cortical neurons and compared with other calcitonin family peptides. We showed that 
these peptides have differential effects on these developmental processes.  
 
 
2. Material and methods 
 
2.1. Dissociation culture of cortical neurons 
 
Rat embryos at embryonic day 16 (E16) and E18 were removed from the pregnant rats 
(Wistar/ST strain, Nihon SLC, Hamamatsu, Japan) under the deep anesthesia by ether. 
Embryos were quickly decapitated and the cerebral cortex was excised. After the 
removal of meninges, whole cerebral cortex was incubated in 0.05% trypsin-EDTA 
(Gibco, Carlsbad, CA) for 5 minutes at 37°C and cells were dissociated by trituration 
with a Pasteur pipette. After filtration with 70-µm nylon cell strainer (BD Falcon, San 
Jose, CA), dissociated cells were plated on 8-well chamber slides (Nunc, Rochester, 
NY) coated with 0.2% polyethyleneimine (Sigma, St. Louis, MO) at a density of 4 X 
104 cells/cm2. The cells were cultured in the minimal essential medium (Gibco) 
supplemented with 10% heat-inactivated fetal bovine serum (Gibco), 0.5 mM 
L-glutamine (Invitrogen, Carlsbad, CA), 25 µM glutamate (Wako, Osaka, Japan) and 
penicillin and streptomycin (25 U/25 µg/ml, Sigma) in a humidified atmosphere of 95% 
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air-5% CO2 at 37°C. For the analysis of dendrite formation, E18 cortical neurons were 
cultured and the culture medium was replaced with the serum free Neurobasal medium 
(Gibco) with 2% B-27 supplement (Gibco), 0.5 mM L-glutamine, penicillin and 
streptomycin (25 U/25 µg/ml) 8 hours after plating. CGRP (Peptide Institute Inc., Osaka, 
Japan), AM (Peptide Institute Inc.), AMY (Peptide Institute Inc.) or CT (Sigma) were 
added in the culture medium at the concentration of 10 nM, 100 nM and 1000 nM. To 
remove proliferating glial cells and neuronal progenitors, 5 µM 
cytosine-β-d-arabinofuranoside (Ara-C, Sigma) was added 1 day after plating for 24 
hours. The absence of astrocytes was confirmed by immunostaining using the antibody 
against glial fibrillary acidic protein (Hayashi et al. 2010). To analyze the dendritic 
protrusions, E16 cortical neurons were cultured in the serum-containing medium for 24 
hours, and then the culture medium was replaced with the above-mentioned serum-free 
Neurobasal medium with 5 µM Ara-C for 24 hours. At 14 days in vitro (DIV), the 
peptides were added for 24 hours. The culture medium was changed every 2 days.  
  All the experiments followed the Guide for the Care and Use of laboratory Animals 
described by the National Institute of Health (USA), and were approved by the Animal 
Experimentation Committee of the University of Tsukuba. 
 
2.2. RNA isolation and reverse transcription PCR 
 
Dissociated cortical cells were plated at a density of 1 X 106 cells/ml on 35-mm culture 
dish (Sumitomo Bakelite, Tokyo, Japan) pre-coated with 0.2% polyethyleneimine. They 
were cultured as described above. At 14 DIV, neurons were washed with 0.01 M 
phosphate-buffered saline (PBS) and the total RNA was extracted by TRIzol Reagent 
(Gibco). Isolated RNA (1 ng-5 µg) was reverse transcribed using the standard protocol 
with Oligo (dT)12-18 (Invitrogen) and SuperScript II Reverse Transcriptase (Invitrogen). 
PCR reactions were performed with 35 cycles of denaturation at 98°C for 10 seconds, 
annealing at 55°C for 30 seconds and extension at 72°C for 1 minute, using TaKaRa EX 
Taq HS (Takara Bio, Shiga, Japan). Oligonucleotide primers for the PCR reactions were 
described in Table 1. The PCR products were resolved on a 2% agarose gel and 
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visualized using ethidium bromide. The size of the bands was confirmed by a 100 bp 
DNA ladder. 
 
2.3. Immunohistochemistry 
 
After the culture, cortical neurons were fixed with 4% paraformaldehyde in 0.1 M 
phosphate buffer (PB) for 30 minutes at room temperature (RT). They were washed 
with 0.1 M PBS containing 0.15% Triton X-100 (TPBS), and nonspecific antibody 
bindings were blocked by incubation with 5% normal goat serum (Gibco) and 0.1% 
Triton X-100 in 0.1 M PB for 30 minutes at RT. For the analysis of the dendrite 
formation, the neurons were incubated with chicken anti-microtubule-associated protein 
2 (MAP2) antibody (1:4000 dilution, Chemicon, Temecula, CA) and mouse 
anti-glutamic acid decarboxylase 65 (GAD65) antibody (1:400 dilution, Sigma) 
overnight at 4°C. They were then incubated with biotinylated goat anti-chicken IgG 
antibody (1:500 dilution, Vector Laboratories, Burlingame, CA) and Alexa Flour 
488-conjugated goat anti-mouse IgG antibody (1:500 dilution, Invitrogen, Eugene, OR) 
for 1 hour at RT, followed by the incubation with Streptavidin Pacific Blue (1:500 
dilution, Invitrogen) for 1 hour at RT. For the analysis of dendritic protrusions, the 
neurons were incubated with rabbit anti-postsynaptic density 95 (PSD95) antibody 
(1:500 dilution, Chemicon) overnight at 4°C. They were then incubated with Alexa 
Flour 488-conjugated goat anti-rabbit IgG antibody (1:500 dilution, Invitrogen) for 1 
hour at RT, followed by the incubation with rhodamine-phalloidin (1:100 dilution, 
Invitrogen) for 30 minutes at RT. 
  For the analysis of the CGRP receptor distribution in vitro, the neurons were 
incubated with rabbit anti-CLR antibody (1:500 dilution, Acris Antibodies GambH, 
Herfod, Germany) or rabbit anti-RAMP1 antibody (1:400 dilution, sc-11379, Santa 
Cruz Biotechnology, Santa Cruz, CA) overnight at 4°C. They were incubated with 
Alexa Flour 488-conjugated goat anti-rabbit IgG antibody (1:500 dilution) for 1 hour at 
RT. Thereafter, the neurons were stained with chicken anti-MAP2 antibody or 
rhodamine-phalloidin as described above. The specificity of the primary antibodies was 
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confirmed by the western blotting and the immunohistochemistry. The western blotting 
using anti-CLR and anti-RAMP1 antibodies showed a band with the prospective size 
(supplemental Fig. 1). The immunostaining without the anti-CLR and anti-RAMP1 
antibodies yielded no positive reaction (data not shown) and the pre-adsorbed 
anti-RAMP1 antibody yielded no positive reaction in cryostat sections (Fig. 8I).  
  For the analysis of the expression of RAMP1 and CGRP in the developing cerebral 
cortex, rats at postnatal day 7 (P7) were perfused transcardially with a fixative 
containing 4% paraformaldehyde in PB under the deep anesthesia. The cerebra were 
excised and immersed in the same fixative overnight at 4˚C. They were immersed 
sequentially in 10%, 20% and 30% sucrose solutions in PB and frozen in Tissue Tek 
O.C.T. compound (Sakura Finetek Japan). Sixteen µm transverse sections were cut and 
collected onto MAS-coated glass slides (Matsunami Glass Ind., Japan). After treatment 
for 30 minutes at RT with 0.3% H2O2 in methanol, the sections were incubated for 1 
hour at RT in a blocking solution containing 5% normal goat serum and 0.1% Triton 
X-100 in PBS. The sections were incubated overnight at 4˚C with rabbit anti-RAMP1 
antibody or rabbit anti-CGRP antibody (1:8000, Chemicon) followed by the incubation 
with the biotinylated secondary antibody (Vector Laboratories; 1:500) for 1 hour at RT. 
The sections were incubated with the peroxidase-conjugated avidin–biotin complex 
(Vector Laboratories; 1:100) for 30 minutes at RT and the positive reactions were 
visualized with diaminobenzidine (DAB) using the ImmunoPure metal enhanced DAB 
substrate kit (Pierce). 
 
2.4. Image acquisition and processing 
 
Images of cultured neurons were acquired using a LSM 510 META laser-scanning 
confocal microscope (Carl Zeiss, Oberkochen, Germany). Images of neurons 
immunostained by antibody against MAP2 in combination with antibodies against 
GAD65, RAMP1 or CLR were acquired using a 20x objective lens. Those labeled by 
anti-PSD95 antibody and rhodamine-phalloidin were acquired at 0.2 µm intervals in 
z-axis direction using a 63x aqua immersion objective lens and stacked. Those labeled 
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by antibodies against RAMP1 or CLR in combination with rhodamine-phalloidin were 
acquired using a 20x objective lens and a 63x aqua immersion objective lens. Those of 
the immunostained cryostat sections were acquired using Axioplan 2 (Carl Zeiss). 
 
2.5. Morphometric analyses 
 
For the analysis of dendrite formation, the total dendritic length, number of primary 
dendrites which extend directly from the cell bodies, average dendritic length (total 
dendritic length/number of primary dendrites) and branching index (number of branch 
points/number of primary dendrites) were measured by an image analyzing software 
(Neurocyte Image Analyser Ver. 1.5, Kurabo, Osaka, Japan) according to Hayashi et al. 
(2010) and Gandou et al (2010). The MAP2-positive longest neurite and the other 
shorter neurites were classified as an axon and dendrites, respectively, as previously 
described (De Lima et al., 1997; Hayashi et al., 2010, Gandou et al., 2010, see also 
Discussion). For the analysis of dendritic protrusions, the protrusions were classified 
into three types: spines with a thin neck and a bulbous head, puncta (stubby spines) 
without neck and 0.5-1.5 µm long, and filopodia 1.5-5 µm long (Gandou et al., 2010). 
The length of dendrite was measured and the number of protrusions per 100 µm length 
of dendrite was calculated. Each experiment was repeated at least 3 times and all the 
analyses were performed blind to the treatment conditions. 
 
2.6. Statistical analyses 
 
All the data were expressed as the mean ± SEM. Statistical analyses were performed by 
ANOVA followed by post hoc analysis (Fisher’s protected least significant difference 
test). Differences were considered significant if the probability of error was less than 
5%. 
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3. Results  
 
3.1. Effects of CGRP treatment on dendrite formation of GAD-negative cortical neurons  
  
E18 cortical neurons were cultured for 2 days or 3 days in the presence of various 
concentrations (10-1000 nM) of CGRP. After the culture, neurons were immunostained 
by antibodies against MAP2 and GAD65 (Fig. 1), and the effects on GAD65-negative 
neurons were analyzed (Fig. 2). At 2D IV, compared to the control, CGRP (10 nM, 100 
nM and 1000 nM) increased the total dendritic length by 35.5±6.7%, 26.1±5.8% and 
24.8±6.1%, and the number of primary dendrites by 23.9±4.0%, 22.1±4.6% and 
24.5±5.4%, respectively (Fig. 2A and B). In contrast, the average dendritic length and 
the branching index were not affected significantly by the CGRP treatment (Fig. 2C and 
D). At 3DIV, CGRP (10 nM, 100 nM and 1000 nM) increased the total dendritic length 
by 32.2±7.7 %, 45.4±6.8% and 23.3±6.7%, respectively (Fig. 2A). CGRP (10 nM, 100 
nM) also increased the number of primary dendrites by 25.9±5.0% and 37.1±5.7%, 
respectively (Fig. 2B). In addition, 1000 nM CGRP increased the branching index by 
71.6±24.4% (Fig. 2D).  
 
3.2. Effects of treatment of calcitonin family peptides on dendrite formation of 
GAD-negative cortical neurons  
 
 We then examined the effects of other calcitonin family peptides (CT, AM and 
AMY) on the dendrite formation of GAD65-negative neurons. E18 cortical neurons 
were cultured for 3 days in the presence of CT, AM or AMY. As compared to the control, 
100 nM AM decreased the total dendritic length by 20.6±2.6%, and 10 nM, 100 nM and 
1000 nM AM decreased the average dendritic length by 11.7±3.8%, 15.6±2.7% and 
15.0±3.2%, respectively (Fig. 3A and C). The number of primary dendrites and the 
branching index were not affected by AM (Fig. 3B and D). Similar to AM, AMY (100 
nM, 1000 nM) decreased the total dendritic length by 10.7±3.8% and 14.4±4.0%, and 
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1000 nM AMY decreased the average dendritic length by 16.1±3.0% (Fig. 3A and C). 
The number of primary dendrites and the branching index were not affected by AMY. 
CT had no significant effect on any parameters of the dendrite formation (Fig. 3).  
  In summary, it was suggested that the treatment of AMY and AM inhibits the 
dendritic elongation of non-GABAergic neurons without effects on the formation of 
primary dendrites nor dendritic branchings.   
   
3.3. Effects of acute treatment of calcitonin family peptides on spine formation 
 
  Growing dendrites have small protrusions on the dendritic shafts, which are classified 
into filopodia, puncta and spines. Among these dendritic protrusions, dendritic spines 
are matured postsynaptic structures at excitatory synapse, and are formed from 
immature filopodia through puncta during the maturation of synapse (Sorra & Harris, 
2000). To examine the effects of CT family peptides on the formation of dendritic 
spines, we cultured E16 cortical neurons for 14 days in the basal medium and then 
added various concentrations (10 nM-1000 nM) of CGRP, AM or AMY for 24 hours. At 
15DIV, we fixed the cortical neurons and stained them by rhodamine-phalloidin and 
anti-PSD95 antibody (Fig. 4).  
  The acute treatment of CGRP (10 nM and 100 nM) increased the density of the 
total protrusions by 18.8±5.1% and 34.4±5.3%, respectively (Fig. 5A). In contrast, 10 
nM and 100 nM AMY decreased it by 13.1±4.4% and 21.6±4.2%, respectively (Fig. 
5G). Among the dendritic protrusions, 10 nM and 100 nM CGRP increased the filopodia 
density by 22.6±8.3% and 45.5±8.6%, respectively (Fig. 5B). CGRP (10 nM, 100 nM 
and 1000 nM) also increased the puncta density by 43.8±9.2%, 32.2±7.2% and 
23.4±8.2%, and 100 nM CGRP increased the spine density by 31.4±5.2%. In contrast, 
10 nM and 100 nM AMY decreased the filopodia density by 19.8±5.1% and 23.3±5.5%, 
respectively, and 100 nM AMY decreased the density of puncta and spines by 
18.5±5.4% and 23.0±4.3%, respectively (Fig. 5H). 100 nM CGRP increased the density 
of PSD-95-immunoreactive protrusions by 33.6±6.7% (Fig. 5C), whereas 100 nM AMY 
decreased it by 18.3±4.3% (Fig. 5I).  AM had a weak effect to decrease the density of 
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filopodia and PSD-95-immunoreactive protrusions (Fig. 5E, F).  
 
3.4. Expression of CGRP receptor components in cultured cortical neurons 
 
  To gain the insight into roles of the CGRP receptor in mediating the effects of CGRP, 
we examined the expression of the receptor components, CLR and RAMP1, in cultured 
neurons by immunohistochemistry. E18 cortical neurons at 3DIV and E16 cortical 
neurons at 14DIV were stained by antibodies against CLR or RAMP1 in combination 
with anti-MAP2 antibody or rhodamine-phalloidin (Fig. 6). At 3DIV, CLR was 
expressed in cell bodies of all neurons, while RAMP1 was expressed both in cell bodies 
and neurites of all neurons (Fig. 6A). At 14DIV, CLR and RAMP1 were expressed in 
the cell bodies of most cortical neurons (Fig. 6B). CLR and RAMP1 were also 
expressed weakly in the dendritic shafts, but no expression was detected in the dendritic 
protrusions (Fig. 6B).  
 
3.5. Expression of receptors for calcitonin family peptides in cultured cortical neurons 
 
  We examined the expression of mRNA of receptor components of calcitonin family 
peptides in E16 cortical neurons at 14DIV. RT-PCR showed that the mRNAs of CTR, 
CLR and RAMP1-3 were expressed in these neurons (Fig. 7).  
 
3.6. Expression of CGRP receptor component and CGRP in developing cerebral cortex 
 
  To find a clue to the role of CGRP in vivo, we localized RAMP1 and CGRP in P7 
cerebral cortex. RAMP1 was expressed in cell bodies of all cortical layers (Fig. 8A). 
The pyramidal neurons in layer V expressed RAMP1 in the apical dendrites as well as 
cell bodies (Fig. 8F). In contrast to the widespread expression of RAMP1, limited 
number of CGRP-positive thin varicose fibers were observed throughout the cortical 
layers (Fig 8C, G, H). 
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4. Discussion   
 
The present study examined roles of calcitonin family peptides in the initial stages of 
the dendrite formation and the maturation of dendritic spines by dissociation culture of 
embryonic cortical neurons. For the analysis of the dendrite formation, we 
immunostained the cortical neurons using the anti-MAP2 antibody which recognizes all 
the subtypes of MAP2. Although MAP2 is distributed abundantly in dendrites and often 
used as the marker of dendrite, MAP2C is also distributed in axons (for a review, see 
Tucker, 1990). A previous study reported that all the neurites (presumptive dendrites 
and axons) of cultured cerebral cortical neurons show MAP2-immunoreactivity at the 
initial stage of the neurite outgrowth, and subsequently the longest neurite loses the 
MAP2-immunoreactivity to differentiate into an axon (De Lima et al., 1997). Our 
previous study confirmed that the MAP2-immunoreactive longest neurite of cultured 
cortical neurons was concomitantly immunoreactive for SMI-31, an axonal marker 
(Hayashi et al., 2010). Therefore, we identified the MAP2-immunoreactive longest 
neurite as a presumptive axon and other shorter neurites as dendrites in the present 
analysis. 
  The present study showed that the chronic treatment of E18 cortical non-GABAergic 
neurons by 10 nM-1000 nM CGRP increased the total dendritic length and the number 
of primary dendrites at 2DIV, and the total dendritic length, the number of primary 
dendrites and the branching index at 3DIV. The increase of the total dendritic length 
may be caused by the increase of the number of primary dendrites, because the average 
dendritic length was not changed. These results suggest that CGRP promotes the 
formation of the primary dendrites (dendrite initiation) without effects on the average 
dendrite length (dendrite elongation). The mechanisms underlying the effects of CGRP 
to promote the dendrite initiation remain to be examined. A similar stimulatory effect of 
the dendrite formation was recently reported in the cerebellar Purkinje cells (D’Antoni 
et al., 2010). It was suggested that the effects on Purkinje cell dendrite may be mediated 
by astrocytes. However, the observed effect on the cortical neurons in the present study 
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seems to be direct, because Ara-C treatment removed astrocytes (Hayashi et al., 2010) 
and the cortical neurons expressed components of the CGRP receptor.  
  In contrast to CGRP, the treatment of AM and AMY decreased the average dendrite 
length without effects on the number of primary dendrites and the branching index. It 
was recently reported that AM and proadrenomedullin (PAMP, N-terminal 20 peptide of 
AM) bind to the cytoskeleton and that reduction of these peptides in vitro leads to the 
hyperpolymerization of tubulin and an increase of the immunoreactivity of 
detyrosinated tubulin (Sackett et al., 2008). In addition, brain-specific knockout of adm 
which leads to the deletion of both AM and PAMP results in the hyperpolymerized 
tubulin in the cerebral cortex (Fernández et al., 2008). These findings suggest that AM 
inhibits the tubulin polymerization, and thus it is likely that AM may inhibit the dendrite 
elongation of cortical neurons by the depolymerization of tubulin. 
   The present study revealed that CGRP promotes the dendrite initiation, whereas AM 
and AMY inhibits the dendrite elongation. The CGRP receptor consists of CLR and 
RAMP1, whereas the AM receptors consist of CLR and RAMP2 or RAMP3, and AMY 
receptors consist of CTR and each of RAMP1-3 (Poyner et al., 2002; Parameswaran and 
Spielman, 2006). Therefore, the different effects of CGRP and AM on the dendrite 
formation may be dependent on RAMP1-3, but not CLR. In addition, the receptors for 
CGRP, AM and AMY are all coupled with Gs which stimulates adenylate cyclase to 
increase the intracellular cAMP concentration. Therefore, the diverse effects of these 
neuropeptides on the dendrite formation cannot be explained simply by the changes of 
the intracellular cAMP. We have recently shown that neurotensin, the receptor of which 
is also coupled with Gs, promotes the dendrite elongation without effects of the number 
of primary dendrites of cortical neurons (Gandoh et al., 2010). These results suggest that 
the neuropeptides regulate various aspects of the dendrite formation through multiple 
signaling pathways. 
  The present study showed that the acute treatment of cortical neurons with CGRP at 
14DIV increased the density of all the dendritic protrusions (filopodia, puncta and 
spines) and PSD95-positive dendritic protrusions. In contrast, the acute treatment with 
AMY had opposite effects by decreasing the density of all the dendritic protrusions and 
 14 
PSD-95 positive protrusions. The mechanisms by the CT family peptides to regulate the 
formation of dendritic protrusions are not known. It was recently reported that serotonin 
2A receptor is distributed in subsets of dendritic spines of cortical neurons and the 
activation of the receptor increases the spine size, suggesting the local action of 
serotonin on spines (Jones et al. 2009). The present immunohistochemical study 
revealed that the receptor components of CGRP (CLR and RAMP1) were localized in 
dendritic shafts as well as cell bodies at 14DIV. However, neither CLR nor RAMP1 was 
detected in the dendritic protrusions. Therefore, the effects of CGRP on the formation of 
dendritic protrusions may be mediated through cell bodies and/or dendritic shafts.  
  The present study showed that CGRP affects the maturation of post-synaptic 
structures. It was previously shown that CGRP increases the synthesis of acetylcholine 
receptors in the neuromuscular junction (New & Mudge, 1986; Fontaine et al., 1986; 
1987; Rossi et al., 2003). Therefore, it is possible that CGRP may be involved in the 
formation of post-synaptic structures both in the central and peripheral nervous systems. 
It may be interesting to determine the effects of CGRP in the development of glutamate 
receptors in the cortical neurons.   
  In conclusion, the present study revealed differential effects of calcitonin family 
peptides in the dendrite formation and spinogenesis of non-GABAergic neurons the 
cerebral cortex in vitro. CGRP promoted both initial dendrite formation and spine 
formation, whereas amylin inhibited both developmental processes and adrenomedullin 
inhibited dendrite formation. It may be possible that CGRP plays a similar role in the 
cortex in vivo, because developing cortical neurons showed a similar expression of the 
CGRP receptor component. In contrast to the ubiquitous expression of the expression of 
the CGRP receptor, CGRP fibers were distributed sparsely, as previously shown in the 
mismatch between the peptide and the receptor for many neuropeptides (Henkenham, 
1987; Kruger et al., 1988; Agnati et al., 1995). The actions of CGRP in vivo may be 
explained by the non-synaptic (volume) transmission through CGRP derived from 
remote axon terminals through extracellular space, cerebrospinal fluid and/or blood 
(Kruger et al., 1988; Agnati et al., 1995). 
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Figure legends 
 
Figure 1 Effects of the CGRP treatment on the dendrite formation of cortical neurons.  
E18 cortical neurons were cultured for 2 days (2DIV) or 3 days (3DIV) in the presence 
of various concentrations (10 nM-1000 nM) of CGRP. After the culture, neurons were 
double-stained with antibodies against MAP2 (red) and GAD65 (green). Arrows 
indicate GAD65-positive neurons. The lower panels at 2 DIV and 3DIV are higher 
magnification views of the areas surrounded by the white square in each upper panel. 
The total dendritic length (TL), the number of primary dendrites (PD), average dendritic 
length (AL) and the branching index (BI) of the typical GAD-negative neurons are 
shown.  Scale bars: 100 µm (upper panels of 2 DIV and 3 DIV), 50 µm (lower panels 
of 2 DIV and 3 DIV), 
 
Figure 2 Effects of the CGRP treatment on the dendrite formation of non-GABAergic 
neurons.  
E18 cortical neurons were cultured for 2 days (2DIV) or 3 days (3DIV) in the presence 
of CGRP and GAD-negative neurons were analyzed. We identified the MAP2-positive 
longest neurite as a presumptive axon, and examined all the other shorter neurites as 
dendrites. The total dendritic length was increased by CGRP (10, 100 and 1000 nM) at 
2DIV and 3DIV (A). The number of primary dendrites was increased by CGRP (10, 100 
and 1000 nM) at 2DIV and by CGRP (10 and 100 nM) at 3DIV (B). The average 
dendritic length was not changed by CGRP (C). The branching index was increased by 
CGRP (1000 nM) at 3DIV (D). The experiment was repeated at 3-4 times, and the 
number of neurons examined in each experimental group is indicated in bars of A. 
Mean ± SEM. *P<0.05, **P<0.01, ***P<0.001 
 
Figure 3 Effects of the treatment of calcitonin family peptides on the dendrite formation 
of non-GABAergic neurons.  
E18 cortical neurons were cultured for 3 days in the presence of various concentrations 
(10 nM-1000 nM) of calcitonin (CT), AM (adrenomedullin) or AMY (amylin), and 
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GAD-negative neurons were analyzed. We identified the MAP2-positive longest neurite 
as a presumptive axon, and examined all the other shorter neurites as dendrites. The 
total dendritic length was decreased by 100 nM AM, and 100 nM and 1000 nM AMY 
(A). The average dendritic length was decreased by AM (10 nM, 100 nM and 1000 nM), 
and 1000 nM AMY (C). The number of primary dendrites and the branching index were 
not changed by any treatment (B, D). The experiment was repeated at 3 times, and the 
neuronal numbers examined in each experimental group are indicated in bars of A. 
Mean ± SEM. *P<0.05, **P<0.01, ***P<0.001 
 
Figure 4 Effects of the acute treatment of calcitonin family peptides on the spine 
formation  
E16 cortical neurons were cultured for 14 days in the basal medium and then treated 
with CGRP, AM (adrenomedullin) or AMY (amylin) for 24 h. Neurons were 
double-stained with anti-PSD95 antibody (green) and rhodamine-phalloidin (red). f: 
filopodia, p: puncta, s: spines. Scale bars: 5 µm.  
 
Figure 5 Differential effects of the acute treatment of calcitonin family peptides on the 
spine formation  
E16 cortical neurons were cultured for 14 days in the basal medium and then treated 
with CGRP (A-C), AM (adrenomedullin; D-F) or AMY (amylin; G-I) for 24 h. CGRP 
increased the density of total protrusions (A), the density of filopodia, puncta and spines 
(B) and the PSD95-immunoreactive protrusions (C). AM decreased the filopodia 
density (E), while increased the PSD95-immunoreactive protrusions (F). AMY 
decreased the density of total protrusions (G), the density of filopodia, puncta and 
spines (H) and the PSD95-immunoreactive protrusions (I).  The experiment was 
repeated 3 times, and the numbers of dendrites examined in each experimental group are 
indicated in bars of A, D and G. Mean ± SEM. *P<0.05, **P<0.01, ***P<0.001. 
  
Figure 6 Expression of CLR and RAMP1 in the cultured cortical neurons. 
 (A) E18 cortical neurons were cultured for 3 days and double-stained with antibodies 
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against MAP2 (red) in combination with CLR (green) or RAMP1 (green). All neurons 
expressed CLR and RAMP1. (B) E16 cortical neurons were cultured for 14 days and 
double-stained with rhodamine-phalloidin to label F-actin (red) in combination with the 
antibodies against CLR (green) or RAMP1 (green). CLR and RAMP1 were expressed 
in the cell bodies and dendritic shafts of most neurons. Scale bars: 50 µm (A, upper 
panels in B and C), 15 µm (lower panel in B and C). 
 
Figure 7 Expression of CT family peptide receptors mRNA in the cultured cortical 
neurons.  
E16 cortical neurons cultured for 14 days and the total RNA was isolated from them. 
RT-PCR was performed for CTR, CLR and RAMP1-3. The mRNAs of all the receptor 
components were detected. Two bands of the CTR were splicing variants. M: 100 bp 
DNA ladder, (+) and (-) show the reaction with and without the reverse transcriptase 
(RT), respectively. 
 
Figure 8 Expression of RAMP1 and CGRP in the postnatal cerebral cortex.  
Cryostat sections of the cerebral cortex at postnatal day 7 were immunostained by the 
anti-RAMP1 antibody (A, F), anti-CGRP antibody (C, G, H) or the antibody 
pre-adsorbed with RAMP1 (I). (A, F) RAMP1 was expressed in cell bodies throughout 
the cortical layers of the parietal cortex, including the apical dendrites of the pyramidal 
neurons (arrowheads in F). F is a higher magnification view of B. (C, G, H) 
CGRP-immunoreactive thin varicose fibers were sparsely distributed in the cortex. G 
and H are higher magnification views of D and E, respectively. (I) The incubation with 
the pre-adsorbed antibody showed no staining. Scale bars: 100 µm (A, C, I), 20 µm 
(F-H). 
   
Supplemental figure legend 
Figure 1 Western blot analyses of anti-CLR and anti-RAMP1 antibody. 
The western blot of cerebral cortex at postnatal day 7 by anti-CLR and anti-RAMP1 
antibodies showed a single positive band with a prospective size. 








